Mauna Kea Technologies has established a shareholder loan agreement with Vester Finance to secure additional funding for commercial growth and development opportunities. The optional financing facility provides up to €4.0 million, available over a period of 24 months, and is repayable in cash or new shares. This arrangement is intended to strengthen the company's momentum in the United States and internationally while supporting geographic expansion into new strategic territories following entries into Switzerland, the United Kingdom, the United Arab Emirates, and Turkey in the first half of 2026.

As of the date of the announcement, no advance has been drawn under the agreement. The company retains the discretion to mobilize the liquidity line based on its needs, with no contractual obligation to draw funds. Current financial visibility extends into the second quarter of 2027 without utilizing this advance or exercising warrants from the November 2025 capital increase.

Principal terms of the loan

Under the agreements dated July 15, 2026, Vester Finance has committed to granting a shareholder loan with a maximum principal amount of €4.0 million. The company may request advances of up to €0.5 million each. If repaid in cash, the advances bear interest at a rate of 7.0% per year from the date of payment and mature on January 15, 2029. The company retains the right to suspend or terminate the agreement at any time without cost.

In the event of repayment in shares, new shares would be issued based on the average stock market price preceding each issuance, with a maximum discount of 5%. The issuance is capped at 24,000,000 new shares, representing at most 12.3% of the current share capital. Assuming full repayment in shares, Vester Finance would hold approximately 21.6% of the company’s share capital on a non-diluted basis and 15.1% on a diluted basis.

Governance and regulatory approval

The transaction was authorized under the 14th resolution of the Combined General Meeting of June 4, 2026, and approved by the company's Board of Directors. It does not require a prospectus approval by the Autorité des marchés financiers (AMF). The number of shares issued under this arrangement will be disclosed in the monthly report on shares and voting rights published on the company's website.

Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated that the arrangement provides valuable financial flexibility to accelerate the commercial adoption of Cellvizio®. The company plans to selectively strengthen its U.S. commercial force and expand the international presence of CellTolerance® using these resources.

Mauna Kea Technologies disclosed the total number of voting rights and shares comprising its share capital as of June 30, 2026. The filing, made in accordance with Article L233-8-II of the Commercial Code and Article 223-16 of the General Regulations of the AMF, provides transparency regarding the company's ownership structure.

The company reported a total of 194,473,901 shares in circulation. The total number of voting rights stood at 195,560,768 on both a gross and net basis. The gross total serves as the basis for calculating thresholds under AMF regulations, while the net total represents voting rights exercisable in General Meeting, excluding shares with suspended voting rights.

Share Capital and Voting Rights Details

The following table outlines the share capital and voting rights distribution as of June 30, 2026:

Regulatory Definitions

(1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.

(2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform. The company is listed on Euronext Growth Paris under the ticker ALMKT.